Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Pancreatic Cancer
PANCREATIC CANCER ADVISOR
FEATURED CONTENT
-
-
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire. -
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials. -
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes. -
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
PANCREATIC CANCER NEWS
Neoadjuvant Urelumab Plus Nivolumab and GVAX for Reresected Pancreatic Cancer
Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
Potential Markers for High Risk of Pancreatic Cancer Identified
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
NALIRIFOX Shows Promising Anticancer Activity in Metastatic Pancreatic Ductal Adenocarcinoma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
